Table 3.
Model variable a | Beta | P value | Model fit ( R 2 ) | Target trough achievement (95% CI) |
---|---|---|---|---|
Model 1: log creatinine |
|
|
0.306 |
35% (28%-42%) |
Intercept |
9.10 |
0.002 |
|
|
Age, years |
0.0886 |
0.002 |
||
Male |
−2.30 |
0.02 |
||
Weight, kg |
−0.0136 |
0.004 |
||
Vancomycin total dose, g |
3.28 |
<0.001 |
||
Every 8-hour interval |
3.18 |
0.1 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−6.61 |
<0.001 |
||
Log baseline creatinine |
8.80 |
<0.001 |
||
Model 2: log cystatin C |
|
|
0.559 |
52% (45%-59%) |
Intercept |
10.2 |
<0.001 |
|
|
Age, years |
−0.00578 |
0.8 |
||
Male |
−2.32 |
0.004 |
||
Weight, kg |
−0.0708 |
0.05 |
||
Vancomycin total dose, g |
2.50 |
<0.001 |
||
Every 8-hour interval |
4.25 |
0.009 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−6.66 |
<0.001 |
||
Log baseline cystatin C |
12.6 |
<0.001 |
||
Model 3: log creatinine and log cystatin C |
|
|
0.575 |
53% (45%-60%) |
Intercept |
11.5 |
<0.001 |
|
|
Age, years |
0.00582 |
0.8 |
||
Male |
−2.64 |
0.001 |
||
Weight, kg |
−0.0931 |
0.01 |
||
Vancomycin total dose, g |
2.70 |
<0.001 |
||
Every 8-hour interval |
4.15 |
0.009 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−7.90 |
<0.001 |
||
Log baseline creatinine |
2.89 |
0.01 |
||
Log baseline cystatin C |
11.3 |
<0.001 |
||
Model 4: eGFR with Cockcroft-Gault |
|
|
0.269 |
33% (26% - 40%) |
Intercept |
10.3 |
<0.001 |
|
|
Vancomycin total dose, g |
2.66 |
<0.001 |
||
Every 8-hour interval |
3.20 |
0.1 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−4.11 |
0.008 |
||
eGFR with Cockcroft-Gault, mL/min |
−0.0704 |
<0.001 |
||
Model 5: eGFR with CKD-EPI
creatinine
|
|
|
0.394 |
38% (31%-46%) |
Intercept |
16.4 |
<0.001 |
|
|
Vancomycin total dose, g |
3.35 |
<0.001 |
||
Every 8-hour interval |
3.47 |
0.06 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−7.58 |
<0.001 |
||
eGFR with CKD-EPIcreatinine, mL/minb |
−0.163 |
<0.001 |
||
Model 6: eGFR with CKD-EPI
cystatin C
|
|
|
0.538 |
51% (44%-59%) |
Intercept |
14.3 |
<0.001 |
|
|
Vancomycin total dose, g |
2.61 |
<0.001 |
||
Every 8-hour interval |
4.91 |
<0.001 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−5.94 |
<0.001 |
||
eGFR with CKD-EPIcystatin C, mL/minb |
−0.134 |
<0.001 |
||
Model 7: eGFR with CKD-EPI
creatinine-cystatin C
|
|
|
0.580 | 54% (45%-61%) |
Intercept |
16.7 |
<0.001 |
||
Vancomycin total dose, g |
2.95 |
<0.001 |
||
Every 8-hour interval |
4.84 |
0.002 |
||
Every 12-hour interval |
REF |
- |
||
Every 24-hour interval |
−7.70 |
<0.001 |
||
eGFR with CKD-EPIcreatinine-cystatin C, mL/minb | −0.163 | <0.001 |
aVancomycin total dose represents the cumulative grams of vancomycin given prior to trough level being drawn. Per the study definition, this represents three doses of vancomycin therapy. bTo convert from milliliters per minute per 1.732, multiply by [(0.007184*height (cm)0.725*weight (kg)0.425)/1.73] [37]. CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaborative; eGFR, estimated glomerular filtration rate; REF, reference.